Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003644 · ClinicalTrials.gov registry record · Phase 3
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
A Phase 3 study of Ovarian Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 571
- Enrollment target
- 20
- Study locations
NCT00003644 is a Phase 3 study of Ovarian Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 571 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00003644, a Phase 3 study of Ovarian Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 571 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether receiving combined carboplatin and paclitaxel plus continued low-dose paclitaxel is more effective than carboplatin and paclitaxel alone for early-stage ovarian cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel alone too see how well they work compared to carboplatin and paclitaxel together with continued low-dose paclitaxel in treating patients with early-stage ovarian cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG paclitaxel
Study Locations (20)
California
- Alta Bates Comprehensive Cancer Center - Berkeley
- Peninsula Medical Center - Burlingame
- Marin Cancer Institute at Marin General Hospital - Greenbrae
- Sutter Health - Western Division Cancer Research Group - Greenbrae
- Todd Cancer Institute at Long Beach Memorial Medical Center - Long Beach
- Kaiser Permanente Medical Center - Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center - Orange
- University of California Davis Cancer Center - Sacramento
- California Pacific Medical Center - California Campus - San Francisco
- Torrance Memorial Medical Center - Torrance
Arizona
- Banner Thunderbird Medical Center - Glendale
- Banner Good Samaritan Medical Center - Phoenix
- CCOP - Western Regional, Arizona - Phoenix
Colorado
- Colorado Gynecologic Oncology Group P.C. - Aurora
- North Colorado Medical Center - Greeley
- McKee Medical Center - Loveland
Arkansas
- Highlands Oncology Group - Fayetteville - Fayetteville
- Washington Regional Medical Center - Fayetteville
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 1998-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003644
The ClinicalTrials.gov registry entry for NCT00003644 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 571 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (21% lower). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.
NCT00003644 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00003644 about?
NCT00003644 is a clinical study titled "Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether receiving combined carboplatin and paclitaxel plus continued low-dose paclitaxel is more effecti...
What is the current status of trial NCT00003644?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 571 participants. The study started on 1998-10.
What conditions does trial NCT00003644 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT00003644?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00003644?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003644 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.